Get the Stockscreener App
61.23
3.17%
1.88
After Hours:
61.14
-0.09
-0.15%
Ionis Pharmaceuticals Inc stock is traded at $61.23, with a volume of 3.20M.
It is up +3.17% in the last 24 hours and up +42.23% over the past month.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
See More
Previous Close:
$59.35
Open:
$59.43
24h Volume:
3.20M
Relative Volume:
1.39
Market Cap:
$9.76B
Revenue:
$705.14M
Net Income/Loss:
$-453.90M
P/E Ratio:
-20.14
EPS:
-3.04
Net Cash Flow:
$-551.29M
1W Performance:
+43.61%
1M Performance:
+42.23%
6M Performance:
+81.42%
1Y Performance:
+27.17%
1-Day Range:
$59.22
$62.01
1-Week Range:
$49.13
$62.08
52-Week Range:
$23.95
$62.08
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Name
Ionis Pharmaceuticals Inc
Sector
Industry
Phone
(760) 931-9200
Address
2855 GAZELLE COURT, CARLSBAD, CA
Compare IONS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
61.23 | 9.46B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-31-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-01-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-07-25 | Initiated | H.C. Wainwright | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Neutral |
| Aug-02-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-16-24 | Resumed | Jefferies | Buy |
| Jun-14-24 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-10-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-02-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-23-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Sep-29-23 | Initiated | Raymond James | Strong Buy |
| Jul-31-23 | Upgrade | Citigroup | Neutral → Buy |
| Jun-07-23 | Resumed | Piper Sandler | Overweight |
| May-04-23 | Upgrade | Citigroup | Sell → Neutral |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Dec-21-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-09-22 | Resumed | Morgan Stanley | Overweight |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-01-22 | Initiated | Citigroup | Sell |
| Mar-01-22 | Initiated | Guggenheim | Buy |
| Feb-01-22 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-07-21 | Upgrade | UBS | Sell → Neutral |
| Mar-01-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Dec-16-20 | Initiated | UBS | Sell |
| Dec-15-20 | Upgrade | Cowen | Market Perform → Outperform |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Sep-02-20 | Initiated | The Benchmark Company | Hold |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Nov-07-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Sep-10-19 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Aug-08-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Reiterated | Stifel | Hold |
| May-08-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-06-17 | Resumed | Goldman | Sell |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Aug-09-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Goldman | Neutral → Sell |
| Dec-28-16 | Reiterated | BMO Capital Markets | Outperform |
| Dec-27-16 | Reiterated | Leerink Partners | Mkt Perform |
View All
Ionis Pharmaceuticals Inc Stock (IONS) Latest News
Does Ionis Pharmaceuticals Inc. stock have upside surprise potentialQuarterly Growth Report & Expert-Curated Trade Recommendations - خودرو بانک
What are analysts’ price targets for Ionis Pharmaceuticals Inc.2025 Key Lessons & Precise Buy Zone Tips - خودرو بانک
Ionis Pharma EVP Baroldi sells $1.95m in shares By Investing.com - Investing.com Australia
Ionis Pharmaceuticals director Wender sells $1.6m in shares By Investing.com - Investing.com South Africa
Is Ionis Pharmaceuticals Inc. a potential multi baggerJuly 2025 Price Swings & Long-Term Safe Return Strategies - خودرو بانک
What is the earnings history of Ionis Pharmaceuticals Inc.Quarterly Profit Report & Smart Swing Trading Techniques - خودرو بانک
Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix - TheStreet
How sentiment analysis helps forecast Ionis Pharmaceuticals Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - Newser
Ionis Pharmaceuticals Stock (IONS) Opinions on Olezarsen Trial Results and FDA Approval - Quiver Quantitative
Ionis pharma EVP O’Neil sells $5.39 million in IONS stock - Investing.com Nigeria
Ionis Pharma EVP Schneider sells $1.19m in shares By Investing.com - Investing.com Nigeria
Ionis gains on late-stage trial win for hypertriglyceridemia therapy - MSN
Market reaction to Ionis Pharmaceuticals Inc.’s recent newsTrade Volume Summary & Long-Term Growth Portfolio Plans - Newser
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 38% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Analyzing Ionis Pharmaceuticals Inc. with risk reward ratio charts2025 Stock Rankings & Expert Curated Trade Ideas - Newser
Assessing Insider Selling at Ionis Pharmaceuticals: Implications for Investor Confidence and Stock Valuation - AInvest
Ionis Pharmaceuticals Insider Sold Shares Worth $2,301,264, According to a Recent SEC Filing - MarketScreener
Ionis Pharmaceuticals Insider Sold Shares Worth $1,946,220, According to a Recent SEC Filing - MarketScreener
Insider Selling at Ionis Pharmaceuticals: A Signal or a Symptom? - AInvest
Real time breakdown of Ionis Pharmaceuticals Inc. stock performanceJuly 2025 Momentum & Low Risk High Reward Trade Ideas - Newser
Ionis Pharma director Klein sells $1.68 million in shares - Investing.com India
Ionis Pharma EVP Baroldi sells $1.95m in shares - Investing.com India
Ionis Pharmaceuticals director sells $1.6m in IONS stock By Investing.com - Investing.com Canada
Ionis pharma EVP Devers sells $192,942 in IONS stock By Investing.com - Investing.com Nigeria
Ionis Pharma EVP Schneider sells $1.19m in shares - Investing.com
SEC Filings Archive 2025-09-04Historical 10-K, 10-Q, 8-K Forms - Stock Titan
Ionis Pharma director Loscalzo sells $962k in shares - Investing.com
Ionis Pharmaceuticals director Klein sells $1.68 million in shares - Investing.com India
Ionis pharma EVP Devers sells $192,942 in IONS stock - Investing.com India
Insider Sell: Brett Monia Sells 203,814 Shares of Ionis Pharmace - GuruFocus
Ionis Pharmaceuticals director Wender sells $1.6m in shares - Investing.com
Ionis Pharmaceuticals CEO Monia sells $12.3 million in IONS stock - Investing.com India
Ionis Pharma EVP Geary sells $503,671 in IONS stock - Investing.com
Ionis Pharmaceuticals director sells $1.6m in IONS stock - Investing.com
How to use a screener to detect Ionis Pharmaceuticals Inc. breakoutsQuarterly Trade Review & Risk Controlled Daily Plans - Newser
Ionis Pharmaceuticals director Klein sells $1.68 million in shares By Investing.com - Investing.com UK
Ionis Pharmaceuticals CEO Monia sells $12.3 million in IONS stock By Investing.com - Investing.com UK
Ionis Pharma (IONS) Hits New High Anew as Analyst Sees Blockbuster Potential for Olezarsen - MSN
Ionis Falls 1.88% with 63% Volume Drop Ranking 457th as BMO Upgrades to 'Outperform' on Breakthrough Drug Outlook - AInvest
Ionis Pharmaceuticals’ Strategic Position in the Biotech Sector: Growth Potential in Therapeutic Innovation and Market Leadership - AInvest
What drives Ionis Pharmaceuticals Inc.’s stock price2025 Volume Leaders & Proven Capital Preservation Methods - خودرو بانک
Is Ionis Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & AI Based Trade Execution Alerts - خودرو بانک
RBC Capital Adjusts Price Target on Ionis Pharmaceuticals to $80 From $70, Maintains Outperform Rating - MarketScreener
Is Ionis Pharmaceuticals Inc. stock entering bullish territoryMarket Activity Report & AI Forecast for Swing Trade Picks - Newser
When is the best time to exit Ionis Pharmaceuticals Inc.July 2025 Momentum & Fast Entry High Yield Stock Tips - Newser
What’s next for Ionis Pharmaceuticals Inc. stock priceDollar Strength & Community Driven Trade Alerts - Newser
Ionis Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - Newser
Building trade automation scripts for Ionis Pharmaceuticals Inc.Market Volume Report & Real-Time Chart Breakout Alerts - Newser
Has Ionis Pharmaceuticals Inc. formed a bullish divergenceJobs Report & Fast Entry Momentum Trade Alerts - Newser
Street Watch: Is Ionis Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Catalysts & Consistent Profit Trade Alerts - خودرو بانک
Ionis Pharmaceuticals Executives Buy Shares Amid Recent Market Volatility. - AInvest
Ionis Pharmaceuticals Inc Stock (IONS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):